US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Global Partners LP

49.76

+0.85001.74%

Post-market: 49.760.00000.00%16:05 EDT

Volume:17.13K

Turnover:854.29K

Market Cap:1.68B

PE:20.65

High:51.08

Open:49.27

Low:48.92

Close:48.91

Loading ...

Overview Company News Filings

MetaVia Reports Additional Positive Top-Line Results From the MAD Part 2 of Its Phase 1 Study of DA-1726, a Novel 3:1 Ratio GLP-1 and Glucagon Dual Receptor Agonist to Treat Obesity, Further Demonstrating Its Best-In-Class Potential

Eli Lilly & Co: Strong Growth Potential in GLP-1 Obesity Market with Positive Financial Outlook

Buy Rating for Structure Therapeutics: Aleniglipron’s Competitive Edge in the Oral GLP-1 Market

Coya Therapeutics Announces Publication of GLP-1/LD IL-2 Combination Biologic (COYA 303) Demonstrating Synergistic Enhancement of Regulatory T Cell Function and Protection Against Treg Apoptosis (Cell Death)

LLY Stock Up as Oral GLP-1 Pill Meets Goals in First Phase III Study

Leerink bullish on Eli Lilly after ‘picture-perfect’ Phase 3 oral GLP-1 results

DarioHealth Collaborates with Leading National Benefit Plan Administrator to Offer Cardiometabolic Solution including a GLP-1 Support Program to Employers

Lilly's oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trial

Hydreight Technologies Expands GLP-1 Portfolio with Liraglutide Launch

EXCLUSIVE: Vivani Medical Collaborates With Okava To Expand Development Of GLP-1 Therapy For Dogs

MetaVia Announces Positive Top-Line Data From the 4-Week Phase 1 MAD Trial of DA-1726, a Novel 3:1 Ratio GLP-1 Glucagon Dual Receptor Agonist to Treat Obesity, Showing Compelling Weight Loss and Safety Effects With Potential Best-In-Class Glucose Control (GLP-1R), Waist Reduction (GCGR), and Tolerability

Viking Therapeutics’ VK2735 Gains Buy Rating Amid Pfizer’s GLP-1 Drug Halt and Promising Trial Results

GLP J-REIT Net Income Climbs 7% in Six Months Ended February

MT Newswires Live

Pfizer discontinues GLP-1 pill trial, stock trades flat

Morgan Stanley sees ‘limited reaction’ in Pfizer shares to oral GLP-1 scrapping

Press Release: Global Partners Announces Cash Distribution on Series B Preferred Units

Pfizer Provides Update on Oral GLP-1 Receptor Agonist Danuglipron

GLP J-REIT Reports Increased Income and Announces Future Earnings Forecast

Strength Seen in Targa Resources (TRGP): Can Its 8.2% Jump Turn into More Strength?

Lexaria Updates its Ongoing Human Study GLP-1-H24-4

ACCESS Newswire

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/GLP/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"GLP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GLP\",,,,,undefined,":{"symbol":"GLP","market":"US","secType":"STK","nameCN":"Global Partners LP","latestPrice":49.76,"timestamp":1745352000000,"preClose":48.91,"halted":0,"volume":17129,"hourTrading":{"tag":"盘后","latestPrice":49.76,"preClose":49.76,"latestTime":"16:05 EDT","volume":1019,"amount":50705.439999999995,"timestamp":1745352312591},"delay":0,"floatShares":25096277,"shares":33668256,"eps":2.41,"marketStatus":"Post-Mkt","change":0.85,"latestTime":"04-22 17:03:30 EDT","open":49.27,"high":51.08,"low":48.915,"amount":854293.1935,"amplitude":0.044265,"askPrice":50.73,"askSize":33,"bidPrice":48.79,"bidSize":18,"shortable":3,"etf":0,"ttmEps":2.41,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1745366400000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1127966400000,"exchange":"NYSE","adjPreClose":48.91,"postHourTrading":{"tag":"盘后","latestPrice":49.76,"preClose":49.76,"latestTime":"16:05 EDT","volume":1019,"amount":50705.439999999995,"timestamp":1745352312591},"volumeRatio":0.552082,"impliedVol":0.4676,"impliedVolPercentile":0.64},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GLP\",,,,,undefined,":{"symbol":"GLP","floatShares":25096277,"roa":"4.19%","roe":"14.20%","lyrEps":2.44604,"volumeRatio":0.552082,"shares":33668256,"dividePrice":2.96,"high":51.08,"amplitude":0.044265,"preClose":48.91,"low":48.915,"week52Low":37.0034,"pbRate":"2.61","psRate":"0.10","week52High":60,"institutionHeld":0.407,"latestPrice":49.76,"committee":-0.294118,"eps":2.41,"divideRate":0.059486,"volume":17129,"delay":0,"ttmEps":2.41,"open":49.27,"prevYearClose":46.55,"prevWeekClose":50.77,"prevMonthClose":53.38,"prevQuarterClose":53.38,"fiveDayClose":49.13,"twentyDayClose":52.68,"sixtyDayClose":51.42},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GLP\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2529304614","title":"MetaVia Reports Additional Positive Top-Line Results From the MAD Part 2 of Its Phase 1 Study of DA-1726, a Novel 3:1 Ratio GLP-1 and Glucagon Dual Receptor Agonist to Treat Obesity, Further Demonstrating Its Best-In-Class Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2529304614","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529304614?lang=en_us&edition=fundamental","pubTime":"2025-04-22 20:31","pubTimestamp":1745325060,"startTime":"0","endTime":"0","summary":"A Dose-Dependent Response in Body Weight Reduction Was Observed Between 8 mg and 32 mg Doses. Change in BMI and Body Weight Adjusted for Height In the Treatment Groups, Showed a Significant Difference Compared to Placebo, Indicating Potentially Greater Efficacy with Increasing Dosage and Longer Duration of Use. No Drug-Induced Cardiovascular Effects Were Observed In Heart Rate or QTcF Measurements of Subjects Receiving up to 32 mg of DA-1726 at 4-Weeks. Additional Cohorts Being Added to Determine Maximum Tolerated Dose. In the 28-day, 36-subject MAD portion of the study, a clear dose-responsive trend in body weight  reduction was observed across the 8 mg to 32 mg range, indicating potentially greater efficacy at higher doses and longer duration of use. Additionally, body mass index , which shows body weight adjusted for height, showed a difference between the treatment group and the placebo  group, which was even more pronounced, further supporting the dose-dependent effect of the drug","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/metavia-reports-additional-positive-top-123100490.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/metavia-reports-additional-positive-top-123100490.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GLP","MTVA"],"gpt_icon":0},{"id":"2529768653","title":"Eli Lilly & Co: Strong Growth Potential in GLP-1 Obesity Market with Positive Financial Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2529768653","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529768653?lang=en_us&edition=fundamental","pubTime":"2025-04-22 18:36","pubTimestamp":1745318171,"startTime":"0","endTime":"0","summary":"Analyst Tim Anderson from Bank of America Securities reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report) and keeping the price target...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/eli-lilly-co-strong-growth-potential-in-glp-1-obesity-market-with-positive-financial-outlook?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/eli-lilly-co-strong-growth-potential-in-glp-1-obesity-market-with-positive-financial-outlook?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SGXZ57979304.SGD","LU0289739699.SGD","GLP","LU2264538146.SGD","LU0094547139.USD","LU0456855351.SGD","LU1035775433.USD","IE0002141913.USD","LU2491050071.SGD","LU0052756011.USD","LU2237443549.SGD","IE00BJT1NW94.SGD","LU0053666078.USD","LU1267930227.SGD","LU0058720904.USD","LU2468319806.SGD","LU1868836591.USD","LU0314106906.USD","SG9999017495.SGD","LU0354030511.USD","LU1201861249.SGD","IE00B4R5TH58.HKD","LLY","LU0203202063.USD","BK4504","LU1232071149.USD","LU1983299246.USD","IE00BLSP4452.SGD","LU0106261372.USD","IE00BZ1G4Q59.USD","LU1718418525.SGD","LU0943347566.SGD","LU2089984988.USD","IE00B7SZLL34.SGD","LU1201861165.SGD","LU2552382132.HKD","IE00BFTCPJ56.SGD","LU0882574139.USD","SG9999001176.SGD","LU0466842654.USD","LU0672654240.SGD","LU0306806265.USD","LU1093756325.SGD","LU2471134523.USD","SG9999014898.SGD","BK4144","LU0096364046.USD","SG9999014880.SGD","LU1974910355.USD"],"gpt_icon":0},{"id":"2529373320","title":"Buy Rating for Structure Therapeutics: Aleniglipron’s Competitive Edge in the Oral GLP-1 Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2529373320","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529373320?lang=en_us&edition=fundamental","pubTime":"2025-04-22 18:16","pubTimestamp":1745316987,"startTime":"0","endTime":"0","summary":"Analyst Ananda Ghosh from H.C. Wainwright maintained a Buy rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR – Research Report) and keepin...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-for-structure-therapeutics-alenigliprons-competitive-edge-in-the-oral-glp-1-market?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-for-structure-therapeutics-alenigliprons-competitive-edge-in-the-oral-glp-1-market?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","GLP"],"gpt_icon":0},{"id":"2529807972","title":"Coya Therapeutics Announces Publication of GLP-1/LD IL-2 Combination Biologic (COYA 303) Demonstrating Synergistic Enhancement of Regulatory T Cell Function and Protection Against Treg Apoptosis (Cell Death)","url":"https://stock-news.laohu8.com/highlight/detail?id=2529807972","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529807972?lang=en_us&edition=fundamental","pubTime":"2025-04-21 21:51","pubTimestamp":1745243460,"startTime":"0","endTime":"0","summary":"COYA 303 is an investigational biologic combination of COYA 301, Coya’s low-dose interleukin 2  and a GLP-1 receptor agonist , designed to deliver a multi-targeted immunomodulatory therapeutic in autoimmune and neurodegenerative diseases. COYA 303 produced a statistically significantly higher Treg suppressive effect on pro-inflammatory myeloid cells and enhanced Treg survival in in vitro human immune cells, compared to the individual components - LD IL-2 and GLP-1RA. Dr. Fred Grossman, Coya’s Chief Medical Officer commented, \"We believe the encouraging results of this study provide support for our multi-targeted combination approach as a potentially viable treatment option for serious and life-threatening conditions of high unmet need driven by chronic inflammation and Treg dysfunction, for which currently av","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/coya-therapeutics-announces-publication-glp-135100483.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GLP","LD","COYA"],"gpt_icon":0},{"id":"2529138887","title":"LLY Stock Up as Oral GLP-1 Pill Meets Goals in First Phase III Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2529138887","media":"Zacks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529138887?lang=en_us&edition=fundamental","pubTime":"2025-04-21 20:37","pubTimestamp":1745239020,"startTime":"0","endTime":"0","summary":"Shares of Eli Lilly LLY soared 14.3% on April 17 after data from a late-stage study showed that orforglipron achieved the primary goal of significantly reducing A1C levels compared to placebo at 40 weeks, with an average A1C reduction of 1.3% to 1.6% from a baseline of 8%. LLY’s orforglipron is an investigational, once-daily small-molecule oral GLP-1 receptor agonist that can be administered at any time of the day without restrictions on food and water intake.The phase III ACHIEVE-1 study, the first of sevenlate-stage studies, is evaluating the safety and efficacy of orforglipron compared to placebo in adults with type 2 diabetes  and inadequate glycemic control with diet and exercise alone. The enrolled patients in the 40-week study were randomized equally to receive either a 3 mg, 12 mg or 36 mg dose of orforglipron or placebo. Lilly is also developing a version of this oral drug for obesity.Year to date, shares of Lilly have gained 8.8% against the industry’s 3.3% decline.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lly-stock-oral-glp-1-123700472.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4532","LU0640476718.USD","LU1035775433.USD","LU1093756325.SGD","LU2089984988.USD","LLY","LU0354030511.USD","LU2360106947.USD","LU0256863811.USD","IE00B2B36J28.USD","LU0456855351.SGD","LU0094547139.USD","LU1023059063.AUD","LU1868836757.USD","LU2361044949.HKD","LU1366192091.USD","LU1868837300.USD","LU1720051108.HKD","SG9999018865.SGD","IE00BK4W5L77.USD","GPCR","BK4581","IE0004445239.USD","LU0238689110.USD","LU1712237335.SGD","SG9999017495.SGD","LU0114720955.EUR","LU1720051017.SGD","LU1548497426.USD","IE00BZ1G4Q59.USD","LU2237443382.USD","LU1061106388.HKD","GLP","LU0417517546.SGD","LU0096364046.USD","VKTX","LU2237443465.HKD","BK4534","LU0471298777.SGD","LU2471134952.CNY","LU0943347566.SGD","LU1093756168.USD","LU2237443622.USD","NVO","LU2264538146.SGD","LU2106854487.HKD","LU2324357040.USD","LU1551013342.USD","III","LU1280957306.USD"],"gpt_icon":1},{"id":"2528748215","title":"Leerink bullish on Eli Lilly after ‘picture-perfect’ Phase 3 oral GLP-1 results","url":"https://stock-news.laohu8.com/highlight/detail?id=2528748215","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528748215?lang=en_us&edition=fundamental","pubTime":"2025-04-17 21:30","pubTimestamp":1744896640,"startTime":"0","endTime":"0","summary":"Leerink notes Eli Lilly’s (LLY) once-daily oral GLP-1 pill showed similar efficacy and safety relative to weekly injectable semaglutide, made by No...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/leerink-bullish-on-eli-lilly-after-picture-perfect-phase-3-oral-glp-1-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/leerink-bullish-on-eli-lilly-after-picture-perfect-phase-3-oral-glp-1-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B4R5TH58.HKD","LU0354030511.USD","LU2471134879.HKD","LU2265009873.SGD","LU2602419157.SGD","IE0002141913.USD","SG9999015945.SGD","SGXZ31699556.SGD","LU1035775433.USD","LU1868837136.USD","LU1988902786.USD","LU1623119135.USD","LU1280957306.USD","LU2237438978.USD","LU2360106947.USD","GLP","LU1868836757.USD","IE00BFTCPJ56.SGD","IE00BK4W5M84.HKD","BK4144","LU0109391861.USD","BK4007","LU1974910355.USD","LU0471298694.HKD","BK4588","LU2112291526.USD","LU1712237335.SGD","LU0882574139.USD","LU0640476718.USD","LU2468319806.SGD","LU0417517546.SGD","LU0122379950.USD","LU0094547139.USD","LLY","SG9999018857.SGD","LU2237443978.SGD","SG9999014906.USD","LU0456855351.SGD","SG9999015952.SGD","LU0058720904.USD","IE00BJJMRZ35.SGD","LU0006306889.USD","LU1720051017.SGD","LU1069344957.HKD","SG9999014880.SGD","LU1868837300.USD","GB00BDT5M118.USD","LU0820561909.HKD","LU1064131342.USD","LU2552382215.SGD"],"gpt_icon":0},{"id":"2528714949","title":"DarioHealth Collaborates with Leading National Benefit Plan Administrator to Offer Cardiometabolic Solution including a GLP-1 Support Program to Employers","url":"https://stock-news.laohu8.com/highlight/detail?id=2528714949","media":"PR Newswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528714949?lang=en_us&edition=fundamental","pubTime":"2025-04-17 20:30","pubTimestamp":1744893000,"startTime":"0","endTime":"0","summary":"Strategic partnership expands Dario's employer footprint and has already started contributing to recurring revenues in Q1 of 2025. \"We are thrilled to partner with one of the fastest growing benefits administrators in the country to support their goals of delivering market-leading health benefits that help reduce costs associated with healthcare,\" said Steven Nelson, Chief Commercial Officer at Dario. \"This strategic partnership unlocks new distribution channels that align with payer-driven models such as Third Party Administrators  and benefits platforms, as well as expanding in the employer market. Due to the shorter sales cycle, we were able to begin onboarding employers quickly after the January launch, with the ability to add employers off-cycle as well, maximizing the availability of Dario's solutions to the employer population and creating an immediate impact on our Business-to-Business-to-Consumer  recurring revenues for 2025. This partnership highlights our solution to the gro","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/dariohealth-collaborates-leading-national-benefit-123000821.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/dariohealth-collaborates-leading-national-benefit-123000821.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GLP","BK4144","EIG","NHLD","BK4590","DRIO","BK4167","BK4107","BK4082"],"gpt_icon":0},{"id":"2528373790","title":"Lilly's oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2528373790","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528373790?lang=en_us&edition=fundamental","pubTime":"2025-04-17 18:45","pubTimestamp":1744886700,"startTime":"0","endTime":"0","summary":"Orforglipron is the first small molecule GLP-1 to successfully complete a Phase 3 trial, lowering A1C by an average of 1.3% to 1.6% across doses. The overall safety and tolerability profile oforforglipron in ACHIEVE-1 was consistent with injectable GLP-1 therapies. In the first Phase 3 trial of the ACHIEVE program, orforglipron met the primary endpoint of superior A1C reduction compared to placebo at 40 weeks, lowering A1C by an average of 1.3% to 1.6% from a baseline of 8.0%, using the efficacy estimand.2 In a key secondary endpoint, more than 65% of participants taking the highest dose of orforglipron achieved an A1C less than or equal to 6.5%, which is below the American Diabetes Association's  defined threshold for diabetes.3 In an additional key secondary endpoint, participants taking orforglipron lost an average of 16.0 lbs  at the highest dose. Given that participants had not yet reached a weight plateau at the time the study ended, it appears that full weight reduction was not ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/lillys-oral-glp-1-orforglipron-104500810.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lillys-oral-glp-1-orforglipron-104500810.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0122379950.USD","LU0820561818.USD","LU1232071149.USD","BK4144","LU2552382058.USD","LU0882574055.USD","LU0289739699.SGD","LLY","LU1551013425.SGD","IE00B1BXHZ80.USD","LU0061475181.USD","IE00BK4W5L77.USD","LU2264538146.SGD","LU0820561909.HKD","SG9999015978.USD","LU2361044949.HKD","LU2237438978.USD","LU2602419157.SGD","SGXZ81514606.USD","LU0882574139.USD","SGXZ31699556.SGD","SGXZ99366536.SGD","LU2237443465.HKD","LU2237443978.SGD","SG9999015945.SGD","BK4590","LU1868836591.USD","LU0238689110.USD","LU0097036916.USD","LU0096364046.USD","LU1061106388.HKD","LU1712237335.SGD","IE00BJLML261.HKD","LU0198837287.USD","LU0354030511.USD","GLP","LU2491050071.SGD","LU0417517546.SGD","LU2023250504.SGD","SGXZ51526630.SGD","BK4585","LU2112291526.USD","LU0640476718.USD","LU0094547139.USD","LU2750360641.GBP","BK4599","SG9999014880.SGD","LU2324357040.USD","LU1983299246.USD","LU1280957306.USD"],"gpt_icon":1},{"id":"2527425992","title":"Hydreight Technologies Expands GLP-1 Portfolio with Liraglutide Launch","url":"https://stock-news.laohu8.com/highlight/detail?id=2527425992","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527425992?lang=en_us&edition=fundamental","pubTime":"2025-04-16 01:03","pubTimestamp":1744736635,"startTime":"0","endTime":"0","summary":"Hydreight Technologies Inc ( ($TSE:NURS) ) has provided an update. Hydreight Technologies Inc. has expanded its VSDHOne platform by launching Lirag...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/hydreight-technologies-expands-glp-1-portfolio-with-liraglutide-launch?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/hydreight-technologies-expands-glp-1-portfolio-with-liraglutide-launch?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GLP","BK4144","BK4590"],"gpt_icon":0},{"id":"2527241371","title":"EXCLUSIVE: Vivani Medical Collaborates With Okava To Expand Development Of GLP-1 Therapy For Dogs","url":"https://stock-news.laohu8.com/highlight/detail?id=2527241371","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527241371?lang=en_us&edition=fundamental","pubTime":"2025-04-15 20:03","pubTimestamp":1744718612,"startTime":"0","endTime":"0","summary":"Vivani Medical, Inc.  and Okava Pharmaceuticals, Inc. expanded their collaboration to include dogs in the development of OKV-119, a long-acting GLP-1 therapy for weight management, diabetes and other cardiometabolic conditions.Financial terms of the expanded agreement were not disclosed.Okava Pharmaceuticals is a clinical-stage company focused on diseases of aging in dogs and cats.Vivani and Okava initiated their collaboration in 2019, focusing on developing OKV-119 for cardiometabolic conditions in cats.Also Read: EXCLUSIVE: Vivani Medical To Spin Off Cortigent Neurostimulation Business To Create Better Focus On Individual Entities And Shareholder Value. OKV-119 leverages Vivani's proprietary NanoPortal technology, which provides smooth and steady delivery of therapeutic molecules, including GLP-1 receptor agonists, over extended periods from a single implant.According to Okava, dosing every six months or longer supports a \"One-and-Done\" approach between office visits consistent with ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exclusive-vivani-medical-collaborates-okava-120332479.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["VANI","BK4590","BK4082","BK4144","GLP"],"gpt_icon":0},{"id":"2527492780","title":"MetaVia Announces Positive Top-Line Data From the 4-Week Phase 1 MAD Trial of DA-1726, a Novel 3:1 Ratio GLP-1 Glucagon Dual Receptor Agonist to Treat Obesity, Showing Compelling Weight Loss and Safety Effects With Potential Best-In-Class Glucose Control (GLP-1R), Waist Reduction (GCGR), and Tolerability","url":"https://stock-news.laohu8.com/highlight/detail?id=2527492780","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527492780?lang=en_us&edition=fundamental","pubTime":"2025-04-15 19:01","pubTimestamp":1744714860,"startTime":"0","endTime":"0","summary":"With No Titration, Demonstrated Compelling Maximum Weight Loss of 6.3% andMean Weight Loss of 4.3% at Day 26 at 32 mg Dose . Demonstrated Strong Signal of GLP-1R Efficacy with Maximum Lowering of Fasted Glucose of -18 mg/dLand Mean Lowering of -5.3 mg/dL at Day 26 at 32 mg Dose. Maximum Waist Circumference Reduction of3.9 Inches and Mean Reduction of 1.6 InchesDemonstrates Strong Signal ofGlucagon Efficacy at Day 33 at 32 mg Dose. Additional Cohorts Being Added to Determine Maximum Tolerated Dose. Planned Phase 1 Part 3 to Include Wegovy Early Drop-Out Patients to Explore Potential Superiority of DA-1726 on Safety and Tolerability, Along With Weight Loss and Other Secondary Endpoints. CAMBRIDGE, Mass., April 15, 2025 /PRNewswire/ -- MetaVia Inc. ,a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced positive results from the 4-week multiple ascending dose  Part 2 of its Phase 1 clinical trial of DA-1726, a novel, dual oxyntomodulin  an","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/metavia-announces-positive-top-line-110100485.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/metavia-announces-positive-top-line-110100485.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BMI","GLP","BK4202","PD","PK","BK4218","BK4181","BK4023","BK4139","LU1169589451.USD","MTVA","BK4157","LU1169590202.USD","BK4590","OXM","BK4144"],"gpt_icon":0},{"id":"2527498293","title":"Viking Therapeutics’ VK2735 Gains Buy Rating Amid Pfizer’s GLP-1 Drug Halt and Promising Trial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2527498293","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527498293?lang=en_us&edition=fundamental","pubTime":"2025-04-15 18:17","pubTimestamp":1744712220,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Michael Ulz from Morgan Stanley reiterated a Buy rating on Viking Therapeutics (VKTX – Research Report), with a pri...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/viking-therapeutics-vk2735-gains-buy-rating-amid-pfizers-glp-1-drug-halt-and-promising-trial-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/viking-therapeutics-vk2735-gains-buy-rating-amid-pfizers-glp-1-drug-halt-and-promising-trial-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VKTX","GLP"],"gpt_icon":0},{"id":"2527124332","title":"GLP J-REIT Net Income Climbs 7% in Six Months Ended February","url":"https://stock-news.laohu8.com/highlight/detail?id=2527124332","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527124332?lang=en_us&edition=fundamental","pubTime":"2025-04-15 07:13","pubTimestamp":1744672436,"startTime":"0","endTime":"0","summary":"GLP J-REIT (TYO:3281) reported a net income of about 15 billion yen for the six months ended Feb. 28, up 7.4% from 14 billion yen the previous half-year period, driven by strong operating performance ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["REIT","CFA.SI","JPY","BK4144","BK4590","GLP"],"gpt_icon":0},{"id":"2527819568","title":"Pfizer discontinues GLP-1 pill trial, stock trades flat","url":"https://stock-news.laohu8.com/highlight/detail?id=2527819568","media":"Yahoo Finance","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527819568?lang=en_us&edition=fundamental","pubTime":"2025-04-14 21:53","pubTimestamp":1744638810,"startTime":"0","endTime":"0","summary":"Pfizer  announced early Monday that it is halting a late-stage trial of its GLP-1 pill candidate, danuglipron, dashing hopes of the company entering the obesity space in the near term.A trial participant in the phase III trial of its once-daily pill experienced \"potential drug-induced liver injury\" that disappeared after the participant stopped the pill, the company said in a statement.Pfizer has been under pressure to find a new blockbuster in its pipeline to fill the expected revenue drop from some of its key drugs going off patent by the end of the decade. That includes its Prevnar 13 vaccine next year and cancer drug Ibrance in 2028. Both brought in a combined $10.8 billion in 2024, with the Prevnar vaccines contributing $6.4 billion.Mizuho healthcare sector expert Jared Holz explained: \"Now without a GLP in its  pipeline, it is now feasible that PFE could look to bring in an asset  should it choose to stay in the weight-loss game to some extent.\". Click here for in-depth analysis ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pfizer-discontinues-glp-1-pill-trial-stock-trades-flat-135330797.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0321505439.SGD","LU0708995401.HKD","BK4532","LU2237443895.HKD","LLY","LU0203202063.USD","LU0097036916.USD","LU0109391861.USD","LU2491050154.USD","LU0820561909.HKD","GLP","LU0823416689.USD","LU2552382058.USD","LU1868837136.USD","NVO","IE00BK4W5L77.USD","LU2602419157.SGD","BK4550","LU0289739699.SGD","LU0170899867.USD","LU1551013425.SGD","LU2491050071.SGD","BK4581","SG9999014898.SGD","LU0225284248.USD","PFE","LU2491049909.HKD","SG9999017495.SGD","LU2023250504.SGD","LU2063271972.USD","LU1720051017.SGD","LU2471134523.USD","LU1883839398.USD","IE0002270589.USD","LU0354030438.USD","IE00B4R5TH58.HKD","LU0456855351.SGD","IE0009355771.USD","LU2552382132.HKD","SG9999015945.SGD","IE00BLSP4452.SGD","BK4599","IE00BLSP4239.USD","LU1983299246.USD","LU2237443622.USD","LU2237443382.USD","LU2360106947.USD","LU1894683348.USD","LU1868837300.USD","BK4533"],"gpt_icon":1},{"id":"2527161066","title":"Morgan Stanley sees ‘limited reaction’ in Pfizer shares to oral GLP-1 scrapping","url":"https://stock-news.laohu8.com/highlight/detail?id=2527161066","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527161066?lang=en_us&edition=fundamental","pubTime":"2025-04-14 21:36","pubTimestamp":1744637805,"startTime":"0","endTime":"0","summary":"Morgan Stanley analyst Terence Flynn notes that Pfizer (PFE) announced that after a review of the totality of the data for its pipeline oral GLP-1 ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/morgan-stanley-sees-limited-reaction-in-pfizer-shares-to-oral-glp-1-scrapping?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/morgan-stanley-sees-limited-reaction-in-pfizer-shares-to-oral-glp-1-scrapping?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0122379950.USD","BK4568","LU1894683264.USD","LU0106831901.USD","LU0985481810.HKD","BK4581","LU1720051108.HKD","IE00BBT3K403.USD","IE0002270589.USD","LU0158827948.USD","BK4127","LU1162221912.USD","LU0158827781.USD","LU2023251221.USD","IE00BZ1G4Q59.USD","SG9999002224.SGD","LU0098860793.USD","LU1989772923.USD","LU0170899867.USD","LU2133065610.SGD","LU1363072403.SGD","LU1720051017.SGD","LU2357305700.SGD","SG9999011175.SGD","LU0306807586.USD","IE00B19Z3B42.SGD","LU0006306889.USD","LU0971096721.USD","PFE","IE00BKVL7J92.USD","LU1023059063.AUD","LU2089284900.SGD","MS","BK4590","LU0267386448.USD","GLP","BK4592","LU0058720904.USD","SG9999001176.SGD","IE000M9KFDE8.USD","LU0306806265.USD","LU0289739699.SGD","LU0314104364.USD","BK4007","BK4599","LU1074936037.SGD","LU0795875169.SGD","BK4144","SG9999003800.SGD","BK4516"],"gpt_icon":0},{"id":"2527150641","title":"Press Release: Global Partners Announces Cash Distribution on Series B Preferred Units","url":"https://stock-news.laohu8.com/highlight/detail?id=2527150641","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527150641?lang=en_us&edition=fundamental","pubTime":"2025-04-14 20:30","pubTimestamp":1744633800,"startTime":"0","endTime":"0","summary":"Global Partners LP   today announced that the Board of Directors  of its general partner, Global GP LLC, has declared a quarterly cash distribution of $0.59375 per unit  on the Partnership's 9.50% fixed-rate Series B preferred units for the period from February 15, 2025 through May 14, 2025. The distribution will be paid on May 15, 2025 to Series B preferred unitholders of record as of the opening of business on May 1, 2025.Global, a master limited partnership, trades on the New York Stock Exchange under the ticker symbol \"GLP.\" For additional information, visit www.globalp.com.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4590","BK4144","GLP"],"gpt_icon":0},{"id":"2527554541","title":"Pfizer Provides Update on Oral GLP-1 Receptor Agonist Danuglipron","url":"https://stock-news.laohu8.com/highlight/detail?id=2527554541","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527554541?lang=en_us&edition=fundamental","pubTime":"2025-04-14 18:45","pubTimestamp":1744627500,"startTime":"0","endTime":"0","summary":"NEW YORK, April 14, 2025----Pfizer Inc.  today announced the decision to discontinue development of danuglipron , an oral glucagon-like peptide-1  receptor agonist, which was being investigated for chronic weight management.Pfizer’s dose-optimization studies of once-daily formulations of danuglipron  met key pharmacokinetic objectives and confirmed a formulation and dose with the potential to deliver a competitive efficacy and tolerability profile in Phase 3 testing, based on earlier studies of twice-daily danuglipron. While the overall frequency of liver enzyme elevations across the over 1,400 participant safety database of danuglipron is in-line with approved agents in the class, a single asymptomatic participant in one of the dose-optimization studies experienced potential drug-induced liver injury which resolved after discontinuation of danuglipron. After a review of the totality of information, including all clinical data generated to date for danuglipron and recent input from reg","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pfizer-provides-oral-glp-1-104500492.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0122379950.USD","BK4592","BK4144","LU0306806265.USD","LU1066051498.USD","LU0289739699.SGD","SG9999002224.SGD","LU0456855351.SGD","IE00BLSP4452.SGD","SG9999011175.SGD","LU0321505868.SGD","SG9999002232.USD","SG9999013999.USD","LU1894683264.USD","BK4534","IE00BBT3K403.USD","LU0321505439.SGD","LU0225284248.USD","LU1023059063.AUD","BK4568","BK4581","SGXZ57979304.SGD","LU0225771236.USD","LU0306807586.USD","IE0002270589.USD","BK4533","BK4590","PFE","LU1883839398.USD","SG9999001176.SGD","IE00B19Z3B42.SGD","LU0868494617.USD","BK4007","IE000M9KFDE8.USD","BK4588","IE00B19Z3581.USD","GLP","LU0058720904.USD","LU1066053197.SGD","LU1057294990.SGD","LU1894683348.USD","SG9999003800.SGD","LU0985481810.HKD","BK4585","BK4599","LU0234572021.USD","SG9999001176.USD","LU0170899867.USD","IE00BLSP4239.USD","BK4550"],"gpt_icon":1},{"id":"2527908666","title":"GLP J-REIT Reports Increased Income and Announces Future Earnings Forecast","url":"https://stock-news.laohu8.com/highlight/detail?id=2527908666","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527908666?lang=en_us&edition=fundamental","pubTime":"2025-04-14 15:09","pubTimestamp":1744614581,"startTime":"0","endTime":"0","summary":"An announcement from GLP J-REIT ( ($JP:3281) ) is now available. GLP J-REIT reported its financial results for the fiscal period ending February 28...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/glp-j-reit-reports-increased-income-and-announces-future-earnings-forecast?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/glp-j-reit-reports-increased-income-and-announces-future-earnings-forecast?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GLP","REIT"],"gpt_icon":0},{"id":"2526598084","title":"Strength Seen in Targa Resources (TRGP): Can Its 8.2% Jump Turn into More Strength?","url":"https://stock-news.laohu8.com/highlight/detail?id=2526598084","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526598084?lang=en_us&edition=fundamental","pubTime":"2025-04-10 19:53","pubTimestamp":1744285980,"startTime":"0","endTime":"0","summary":"Targa Resources, Inc.  shares ended the last trading session 8.2% higher at $173.65. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 11.4% loss over the past four weeks.Targa Resources saw its stock price rise as natural gas prices followed the upward trend in oil prices. The energy infrastructure company benefited from the broader market rally that was sparked by President Trump’s decision to pause tariff hikes and reduce tariff rates. This policy changes reduced concerns about trade barriers and their impact on energy-related businesses like Targa. With investor confidence restored, Targa’s stock rose, driven by both the higher oil and natural gas prices and the positive economic outlook from the temporary tariff pause and reduced tariff rates.For Targa Resources, the consensus EPS estimate for the quarter has been revised 4.1% higher over the last 30 days to the current level. And a positiv","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/strength-seen-targa-resources-trgp-115300297.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0456854461.SGD","TRGP","LU0788109394.HKD","BK4585","BK4590","GLP","BK4144","BK4588","LU0368265418.SGD","LU0122376428.USD","LU0266512127.USD"],"gpt_icon":0},{"id":"2524487257","title":"Lexaria Updates its Ongoing Human Study GLP-1-H24-4","url":"https://stock-news.laohu8.com/highlight/detail?id=2524487257","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524487257?lang=en_us&edition=fundamental","pubTime":"2025-04-03 21:10","pubTimestamp":1743685800,"startTime":"0","endTime":"0","summary":"Registered Phase-1b 12-week study investigating safety, diabetes control, and weight loss. KELOWNA, BC / ACCESS Newswire / April 3, 2025 / Lexaria Bioscience Corp.  , a global innovator in drug delivery platforms, is pleased to provide this progress update on its Phase 1b, 12-week chronic study GLP-1-H24-4  underway in Australia.\"Lexaria is pleased to have reached LPI enrollment completion,\" said John Docherty, President and Chief Scientific Officer of Lexaria Bioscience Corp. \"Dosing is progressing nicely and, at this point, we are expecting the Study to complete on schedule.\". Arm 1 of the Study is utilizing a proprietary, patented DehydraTECH-CBD formulation. Our 2022 diabetes animal study DIAB-A22-1, utilizing DehydraTECH-CBD evidenced weight loss of 7% and reduced blood glucose levels of 19.9%+/-7%  during a multi-week rodent study without the addition of any GLP-1 drugs. Lexaria is looking forward to discovering in humans whether DehydraTECH-CBD studied alone, or together with De","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lexaria-updates-ongoing-human-study-131000178.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4144","LEXXW","BK4007","ACB","GLP","BK4590","BK4557","LEXX"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GLP\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-02-28","symbol":"GLP","fiscalQuarterEnding":"2024/12","expectedEps":0.24,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1740718800000,"reportTimeType":"pre","actualEps":0.52},{"date":"2025-02-10","symbol":"GLP","amount":0.74,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-02-10","defaultRemindTime":1739197800000,"name":"全球合伙","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-02-14","payableDate":"2025-02-10","currency":"USD","dateTimestamp":1739163600000,"payDate":"2025-02-14"},{"date":"2024-11-08","symbol":"GLP","amount":0.73,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-11-08","defaultRemindTime":1731076200000,"name":"全球合伙","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-11-14","payableDate":"2024-11-08","currency":"USD","dateTimestamp":1731042000000,"payDate":"2024-11-14"},{"market":"US","date":"2024-11-08","symbol":"GLP","fiscalQuarterEnding":"2024/09","expectedEps":1.57,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731042000000,"reportTimeType":"pre","actualEps":1.17},{"date":"2024-08-08","symbol":"GLP","amount":0.72,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-08-08","defaultRemindTime":1723123800000,"name":"全球合伙","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-08-14","payableDate":"2024-08-08","currency":"USD","dateTimestamp":1723089600000,"payDate":"2024-08-14"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GLP\",market:\"US\",,,undefined,":[{"executeDate":"2015-05-04","recordDate":"2015-05-06","paymentDate":"2015-05-15","value":0.68,"currency":"USD"},{"executeDate":"2015-08-03","recordDate":"2015-08-05","paymentDate":"2015-08-14","value":0.6925,"currency":"USD"},{"executeDate":"2015-11-02","recordDate":"2015-11-04","paymentDate":"2015-11-13","value":0.6975,"currency":"USD"},{"executeDate":"2016-02-08","recordDate":"2016-02-10","paymentDate":"2016-02-16","value":0.4625,"currency":"USD"},{"executeDate":"2016-05-04","recordDate":"2016-05-06","paymentDate":"2016-05-16","value":0.4625,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GLP\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":1,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":1,"analysts":2,"updateTime":1741233600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/GLP\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"GLP","date":"2025-04-21","current":18.509538,"percent":0.885273,"low":2.771386,"twenty":4.270877,"median":9.726256,"eighty":15.350956,"high":29.34912,"avg":10.428443,"sd":6.24379,"marketCap":1709337357},"quantilePoints":[{"date":"2020-04-24","current":10.885399,"twenty":6.299451,"median":7.87934,"eighty":11.115597,"marketCap":375415632},{"date":"2020-05-01","current":11.300646,"twenty":6.299659,"median":7.88907,"eighty":11.255307,"marketCap":389736665},{"date":"2020-05-08","current":11.690231,"twenty":6.299659,"median":7.896854,"eighty":11.255307,"marketCap":361461939},{"date":"2020-05-15","current":10.863092,"twenty":6.299659,"median":7.912422,"eighty":11.245121,"marketCap":335886802},{"date":"2020-05-22","current":11.182919,"twenty":6.299659,"median":7.932539,"eighty":11.262234,"marketCap":345775855},{"date":"2020-05-29","current":11.24909,"twenty":6.299659,"median":7.943558,"eighty":11.269162,"marketCap":347821866},{"date":"2020-06-05","current":12.451199,"twenty":6.307959,"median":7.955234,"eighty":11.298028,"marketCap":384991066},{"date":"2020-06-12","current":11.557889,"twenty":6.309309,"median":7.998046,"eighty":11.32112,"marketCap":357369917},{"date":"2020-06-19","current":11.072634,"twenty":6.3117,"median":8.066523,"eighty":11.332667,"marketCap":342365837},{"date":"2020-06-26","current":10.708693,"twenty":6.3117,"median":8.171888,"eighty":11.326893,"marketCap":331112776},{"date":"2020-07-02","current":10.752807,"twenty":6.317715,"median":8.211094,"eighty":11.322275,"marketCap":332476784},{"date":"2020-07-10","current":10.43298,"twenty":6.321861,"median":8.267451,"eighty":11.32112,"marketCap":322587731},{"date":"2020-07-17","current":10.13521,"twenty":6.32825,"median":8.287054,"eighty":11.316433,"marketCap":313380681},{"date":"2020-07-24","current":10.543265,"twenty":6.333279,"median":8.291955,"eighty":11.303569,"marketCap":325997749},{"date":"2020-07-31","current":11.800516,"twenty":6.334178,"median":8.348313,"eighty":11.303569,"marketCap":364871958},{"date":"2020-08-07","current":4.73435,"twenty":6.333279,"median":8.360564,"eighty":11.32112,"marketCap":438154667},{"date":"2020-08-14","current":5.006778,"twenty":6.3117,"median":8.298445,"eighty":11.316433,"marketCap":463367300},{"date":"2020-08-21","current":4.712262,"twenty":6.299659,"median":8.287054,"eighty":11.303569,"marketCap":436110400},{"date":"2020-08-28","current":4.701217,"twenty":6.299607,"median":8.274802,"eighty":11.298552,"marketCap":435088266},{"date":"2020-09-04","current":4.542915,"twenty":6.2824,"median":8.213544,"eighty":11.285346,"marketCap":420437682},{"date":"2020-09-11","current":4.749076,"twenty":6.27606,"median":8.174338,"eighty":11.274368,"marketCap":439517512},{"date":"2020-09-18","current":4.815342,"twenty":6.275736,"median":8.086126,"eighty":11.269162,"marketCap":445650315},{"date":"2020-09-25","current":4.73435,"twenty":6.258044,"median":8.00583,"eighty":11.265698,"marketCap":438154667},{"date":"2020-10-02","current":4.933149,"twenty":6.250305,"median":7.971673,"eighty":11.259925,"marketCap":456553075},{"date":"2020-10-09","current":5.360198,"twenty":6.244429,"median":7.94745,"eighty":11.2525,"marketCap":496075580},{"date":"2020-10-16","current":5.26448,"twenty":6.239772,"median":7.932539,"eighty":11.247278,"marketCap":487217087},{"date":"2020-10-23","current":5.271843,"twenty":6.23717,"median":7.912422,"eighty":11.243223,"marketCap":487898510},{"date":"2020-10-30","current":5.338109,"twenty":6.227089,"median":7.896854,"eighty":11.239367,"marketCap":494031312},{"date":"2020-11-06","current":5.459545,"twenty":6.22179,"median":7.88907,"eighty":11.21862,"marketCap":522855188},{"date":"2020-11-13","current":5.670214,"twenty":6.203808,"median":7.87934,"eighty":11.19873,"marketCap":543030764},{"date":"2020-11-20","current":5.877313,"twenty":6.196135,"median":7.85015,"eighty":11.194013,"marketCap":562864382},{"date":"2020-11-27","current":6.170107,"twenty":6.185826,"median":7.85015,"eighty":11.189536,"marketCap":590905013},{"date":"2020-12-04","current":6.109406,"twenty":6.168749,"median":7.838474,"eighty":11.169685,"marketCap":585091712},{"date":"2020-12-11","current":6.416483,"twenty":6.167844,"median":7.834582,"eighty":11.145422,"marketCap":614500179},{"date":"2020-12-18","current":6.230809,"twenty":6.167844,"median":7.828744,"eighty":11.130907,"marketCap":596718315},{"date":"2020-12-24","current":6.048705,"twenty":6.167844,"median":7.82096,"eighty":11.115597,"marketCap":579278410},{"date":"2020-12-31","current":5.934444,"twenty":6.167844,"median":7.817068,"eighty":11.101741,"marketCap":568335725},{"date":"2021-01-08","current":6.062987,"twenty":6.149862,"median":7.795662,"eighty":11.084422,"marketCap":580646246},{"date":"2021-01-15","current":6.216526,"twenty":6.149862,"median":7.785585,"eighty":11.084422,"marketCap":595350479},{"date":"2021-01-22","current":6.705707,"twenty":6.149862,"median":7.780094,"eighty":11.074992,"marketCap":642198851},{"date":"2021-01-29","current":7.180605,"twenty":6.149862,"median":7.776202,"eighty":11.068208,"marketCap":687679388},{"date":"2021-02-05","current":7.284155,"twenty":6.149862,"median":7.768418,"eighty":11.06411,"marketCap":697596196},{"date":"2021-02-12","current":6.934229,"twenty":6.163202,"median":7.760634,"eighty":11.053134,"marketCap":664084222},{"date":"2021-02-19","current":7.112763,"twenty":6.167321,"median":7.75285,"eighty":11.04396,"marketCap":681182168},{"date":"2021-02-26","current":7.202029,"twenty":6.167844,"median":7.741174,"eighty":11.038761,"marketCap":689731141},{"date":"2021-03-05","current":6.896217,"twenty":6.167844,"median":7.718575,"eighty":11.032407,"marketCap":695214499},{"date":"2021-03-12","current":7.842623,"twenty":6.167844,"median":7.698362,"eighty":11.017031,"marketCap":790622686},{"date":"2021-03-19","current":7.720506,"twenty":6.167844,"median":7.718575,"eighty":11.007626,"marketCap":778311953},{"date":"2021-03-26","current":7.411822,"twenty":6.167844,"median":7.69367,"eighty":11.00501,"marketCap":747193153},{"date":"2021-04-01","current":7.320234,"twenty":6.167844,"median":7.686686,"eighty":10.988222,"marketCap":737960103},{"date":"2021-04-09","current":7.3779,"twenty":6.167844,"median":7.67501,"eighty":10.954813,"marketCap":743773505},{"date":"2021-04-16","current":7.510194,"twenty":6.168749,"median":7.659442,"eighty":10.940212,"marketCap":757110133},{"date":"2021-04-23","current":7.364332,"twenty":6.170107,"median":7.594997,"eighty":10.930856,"marketCap":742405645},{"date":"2021-04-30","current":8.185229,"twenty":6.171613,"median":7.641929,"eighty":10.912383,"marketCap":825161134},{"date":"2021-05-07","current":9.181725,"twenty":6.178654,"median":7.67501,"eighty":10.905455,"marketCap":849502414},{"date":"2021-05-14","current":8.749253,"twenty":6.185826,"median":7.686686,"eighty":10.905455,"marketCap":809489619},{"date":"2021-05-21","current":9.203903,"twenty":6.185826,"median":7.690578,"eighty":10.897433,"marketCap":851554353},{"date":"2021-05-28","current":9.407203,"twenty":6.185826,"median":7.712361,"eighty":10.877257,"marketCap":870363786},{"date":"2021-06-04","current":9.706607,"twenty":6.189262,"median":7.720506,"eighty":10.864653,"marketCap":898064952},{"date":"2021-06-11","current":10.061456,"twenty":6.203126,"median":7.741174,"eighty":10.858681,"marketCap":930895963},{"date":"2021-06-18","current":9.603109,"twenty":6.203644,"median":7.748958,"eighty":10.836624,"marketCap":888489240},{"date":"2021-06-25","current":9.680732,"twenty":6.203808,"median":7.760634,"eighty":10.817799,"marketCap":895671024},{"date":"2021-07-02","current":9.658554,"twenty":6.203808,"median":7.768418,"eighty":10.809851,"marketCap":893619086},{"date":"2021-07-09","current":9.31849,"twenty":6.203808,"median":7.778148,"eighty":10.796921,"marketCap":862156033},{"date":"2021-07-16","current":8.963641,"twenty":6.213362,"median":7.780094,"eighty":10.785892,"marketCap":829325022},{"date":"2021-07-23","current":9.495915,"twenty":6.213362,"median":7.785616,"eighty":10.763835,"marketCap":878571539},{"date":"2021-07-30","current":9.909906,"twenty":6.216526,"median":7.795662,"eighty":10.752807,"marketCap":916874385},{"date":"2021-08-06","current":29.34912,"twenty":6.22179,"median":7.817068,"eighty":10.752807,"marketCap":823536295},{"date":"2021-08-13","current":26.023372,"twenty":6.22179,"median":7.822906,"eighty":10.813084,"marketCap":730215805},{"date":"2021-08-20","current":24.554702,"twenty":6.22179,"median":7.83069,"eighty":10.865043,"marketCap":689004931},{"date":"2021-08-27","current":24.530426,"twenty":6.22179,"median":7.834582,"eighty":10.905455,"marketCap":688323760},{"date":"2021-09-03","current":25.100901,"twenty":6.22179,"median":7.842494,"eighty":10.964493,"marketCap":704331289},{"date":"2021-09-10","current":24.275533,"twenty":6.228856,"median":7.848204,"eighty":11.013201,"marketCap":681171460},{"date":"2021-09-17","current":25.198003,"twenty":6.230622,"median":7.85015,"eighty":11.053134,"marketCap":707055975},{"date":"2021-09-24","current":24.894559,"twenty":6.230772,"median":7.876969,"eighty":11.084422,"marketCap":698541332},{"date":"2021-10-01","current":26.047647,"twenty":6.233421,"median":7.883329,"eighty":11.141011,"marketCap":730896976},{"date":"2021-10-08","current":26.897291,"twenty":6.234318,"median":7.892962,"eighty":11.19642,"marketCap":754737977},{"date":"2021-10-15","current":26.836602,"twenty":6.236185,"median":7.896854,"eighty":11.246674,"marketCap":753035049},{"date":"2021-10-22","current":28.632991,"twenty":6.237348,"median":7.914368,"eighty":11.269162,"marketCap":803441737},{"date":"2021-10-29","current":28.329547,"twenty":6.237865,"median":7.935774,"eighty":11.303569,"marketCap":794927093},{"date":"2021-11-05","current":18.151279,"twenty":6.239408,"median":7.94745,"eighty":11.328048,"marketCap":776838422},{"date":"2021-11-12","current":18.191189,"twenty":6.239772,"median":7.988112,"eighty":11.346522,"marketCap":778546510},{"date":"2021-11-19","current":18.773882,"twenty":6.239772,"median":8.014118,"eighty":11.360961,"marketCap":803484595},{"date":"2021-11-26","current":18.694061,"twenty":6.239772,"median":8.035981,"eighty":11.378852,"marketCap":800068419},{"date":"2021-12-03","current":18.103386,"twenty":6.239772,"median":8.105729,"eighty":11.403489,"marketCap":774788716},{"date":"2021-12-10","current":18.430652,"twenty":6.240495,"median":8.179783,"eighty":11.427136,"marketCap":788795038},{"date":"2021-12-17","current":18.550383,"twenty":6.243048,"median":8.213544,"eighty":11.470285,"marketCap":793919302},{"date":"2021-12-23","current":17.991637,"twenty":6.244429,"median":8.252749,"eighty":11.474686,"marketCap":770006070},{"date":"2021-12-31","current":18.749936,"twenty":6.244429,"median":8.284603,"eighty":11.575574,"marketCap":802459742},{"date":"2022-01-07","current":20.051017,"twenty":6.24581,"median":8.291955,"eighty":11.616705,"marketCap":858143411},{"date":"2022-01-14","current":21.152545,"twenty":6.248234,"median":8.320498,"eighty":11.690231,"marketCap":905286640},{"date":"2022-01-21","current":20.146802,"twenty":6.249277,"median":8.363015,"eighty":11.729858,"marketCap":862242822},{"date":"2022-01-28","current":21.392008,"twenty":6.251718,"median":8.365465,"eighty":11.776801,"marketCap":915535168},{"date":"2022-02-04","current":21.85497,"twenty":6.254157,"median":8.433466,"eighty":11.837284,"marketCap":935348988},{"date":"2022-02-11","current":21.559632,"twenty":6.257754,"median":8.47328,"eighty":11.938846,"marketCap":922709137},{"date":"2022-02-18","current":20.945011,"twenty":6.257851,"median":8.48054,"eighty":12.432666,"marketCap":896404582},{"date":"2022-02-25","current":20.529942,"twenty":6.258237,"median":8.487891,"eighty":12.775373,"marketCap":878640467},{"date":"2022-03-04","current":15.348683,"twenty":6.268592,"median":8.571294,"eighty":13.121553,"marketCap":878174885},{"date":"2022-03-11","current":15.504022,"twenty":6.275496,"median":8.601399,"eighty":13.154839,"marketCap":887062603},{"date":"2022-03-18","current":15.940166,"twenty":6.275736,"median":8.649704,"eighty":13.201441,"marketCap":912016580},{"date":"2022-03-25","current":16.890123,"twenty":6.275736,"median":8.669307,"eighty":13.248042,"marketCap":966368393},{"date":"2022-04-01","current":16.214996,"twenty":6.275736,"median":8.68891,"eighty":13.261356,"marketCap":927741004},{"date":"2022-04-08","current":16.752708,"twenty":6.275736,"median":8.726599,"eighty":13.281328,"marketCap":958506181},{"date":"2022-04-14","current":16.573471,"twenty":6.275736,"median":8.736337,"eighty":13.3013,"marketCap":948251122},{"date":"2022-04-22","current":16.011861,"twenty":6.276168,"median":8.777122,"eighty":13.329261,"marketCap":916118604},{"date":"2022-04-29","current":15.743005,"twenty":6.281175,"median":8.797306,"eighty":13.342575,"marketCap":900736015},{"date":"2022-05-06","current":9.804164,"twenty":6.2824,"median":8.848712,"eighty":13.349233,"marketCap":897659497},{"date":"2022-05-13","current":9.69216,"twenty":6.2824,"median":8.9103,"eighty":13.347901,"marketCap":887404438},{"date":"2022-05-20","current":10.270852,"twenty":6.291454,"median":8.930374,"eighty":13.347901,"marketCap":940388910},{"date":"2022-05-27","current":11.163158,"twenty":6.293718,"median":8.972794,"eighty":13.342575,"marketCap":1022087547},{"date":"2022-06-03","current":10.868211,"twenty":6.294536,"median":8.995202,"eighty":13.341244,"marketCap":995082558},{"date":"2022-06-10","current":10.244717,"twenty":6.297672,"median":9.026396,"eighty":13.341244,"marketCap":937996063},{"date":"2022-06-17","current":7.754474,"twenty":6.299555,"median":9.016925,"eighty":13.33725,"marketCap":709991918},{"date":"2022-06-24","current":8.613179,"twenty":6.299659,"median":8.99034,"eighty":13.331924,"marketCap":788614037},{"date":"2022-07-01","current":8.814788,"twenty":6.299659,"median":8.977241,"eighty":13.322603,"marketCap":807073143},{"date":"2022-07-08","current":8.900658,"twenty":6.299659,"median":8.963641,"eighty":13.313284,"marketCap":814935355},{"date":"2022-07-15","current":8.867057,"twenty":6.299659,"median":8.92485,"eighty":13.306626,"marketCap":811858837},{"date":"2022-07-22","current":9.561487,"twenty":6.300172,"median":8.963641,"eighty":13.3013,"marketCap":875440203},{"date":"2022-07-29","current":10.371656,"twenty":6.303369,"median":8.980096,"eighty":13.299969,"marketCap":949618463},{"date":"2022-08-05","current":3.850073,"twenty":6.303369,"median":8.997729,"eighty":13.29198,"marketCap":927520968},{"date":"2022-08-12","current":4.016293,"twenty":6.299659,"median":8.972794,"eighty":13.281328,"marketCap":967565231},{"date":"2022-08-19","current":3.999245,"twenty":6.293991,"median":8.937993,"eighty":13.278687,"marketCap":963458127},{"date":"2022-08-26","current":3.899797,"twenty":6.2824,"median":8.919306,"eighty":13.268103,"marketCap":939500021},{"date":"2022-09-02","current":4.077383,"twenty":6.275736,"median":8.9103,"eighty":13.268014,"marketCap":982282354},{"date":"2022-09-09","current":4.169728,"twenty":6.275496,"median":8.900658,"eighty":13.268014,"marketCap":1004529167},{"date":"2022-09-16","current":4.014873,"twenty":6.257754,"median":8.857885,"eighty":13.261356,"marketCap":967222973},{"date":"2022-09-23","current":3.607134,"twenty":6.247881,"median":8.814788,"eighty":13.254699,"marketCap":868994737},{"date":"2022-09-30","current":3.51621,"twenty":6.240977,"median":8.791187,"eighty":13.254699,"marketCap":847090183},{"date":"2022-10-07","current":3.916845,"twenty":6.239772,"median":8.777122,"eighty":13.248042,"marketCap":943607125},{"date":"2022-10-14","current":3.740679,"twenty":6.236636,"median":8.755886,"eighty":13.248042,"marketCap":901167051},{"date":"2022-10-21","current":4.087328,"twenty":6.230622,"median":8.734756,"eighty":13.241384,"marketCap":984678164},{"date":"2022-10-28","current":4.250707,"twenty":6.22179,"median":8.716798,"eighty":13.234727,"marketCap":1024037910},{"date":"2022-11-04","current":3.449288,"twenty":6.213362,"median":8.68891,"eighty":13.208098,"marketCap":1095762902},{"date":"2022-11-11","current":3.301892,"twenty":6.203808,"median":8.669307,"eighty":13.201441,"marketCap":1048938349},{"date":"2022-11-18","current":3.311575,"twenty":6.185826,"median":8.649704,"eighty":13.194783,"marketCap":1052014414},{"date":"2022-11-25","current":3.399797,"twenty":6.17312,"median":8.639313,"eighty":13.17348,"marketCap":1080040789},{"date":"2022-12-02","current":3.385811,"twenty":6.167844,"median":8.62969,"eighty":13.162828,"marketCap":1075597583},{"date":"2022-12-09","current":3.518145,"twenty":6.167844,"median":8.601399,"eighty":13.156171,"marketCap":1117637146},{"date":"2022-12-16","current":3.574091,"twenty":6.149862,"median":8.577106,"eighty":13.154839,"marketCap":1135409969},{"date":"2022-12-23","current":3.865656,"twenty":6.146266,"median":8.549709,"eighty":13.144188,"marketCap":1228033720},{"date":"2022-12-30","current":3.740853,"twenty":6.130032,"median":8.492883,"eighty":13.133536,"marketCap":1188386653},{"date":"2023-01-06","current":3.441757,"twenty":6.130032,"median":8.492883,"eighty":13.133536,"marketCap":1093370406},{"date":"2023-01-13","current":3.612823,"twenty":6.130032,"median":8.492883,"eighty":13.133536,"marketCap":1147714231},{"date":"2023-01-20","current":3.620354,"twenty":6.130032,"median":8.492883,"eighty":13.133536,"marketCap":1150106726},{"date":"2023-01-27","current":3.857048,"twenty":6.130032,"median":8.492883,"eighty":13.133536,"marketCap":1225299440},{"date":"2023-02-03","current":4.130323,"twenty":6.130032,"median":8.492883,"eighty":13.133536,"marketCap":1312112845},{"date":"2023-02-10","current":3.93774,"twenty":6.130032,"median":8.492883,"eighty":13.133536,"marketCap":1250933319},{"date":"2023-02-17","current":3.875339,"twenty":6.130032,"median":8.492883,"eighty":13.133536,"marketCap":1231109786},{"date":"2023-02-24","current":3.718259,"twenty":6.130032,"median":8.492883,"eighty":13.133536,"marketCap":1181209167},{"date":"2023-03-03","current":3.363192,"twenty":6.130032,"median":8.492883,"eighty":13.133536,"marketCap":1194165378},{"date":"2023-03-10","current":3.211151,"twenty":6.113691,"median":8.482899,"eighty":13.133536,"marketCap":1140180220},{"date":"2023-03-17","current":2.830086,"twenty":6.097582,"median":8.463126,"eighty":13.133536,"marketCap":1004875645},{"date":"2023-03-24","current":2.875313,"twenty":6.070129,"median":8.365465,"eighty":13.133536,"marketCap":1020934521},{"date":"2023-03-31","current":2.985014,"twenty":6.034422,"median":8.291955,"eighty":13.130873,"marketCap":1059885838},{"date":"2023-04-06","current":2.892634,"twenty":6.016569,"median":8.274802,"eighty":13.130873,"marketCap":1027084729},{"date":"2023-04-14","current":2.896483,"twenty":5.960153,"median":8.185229,"eighty":13.133536,"marketCap":1028451442},{"date":"2023-04-20","current":2.925352,"twenty":5.879004,"median":8.105729,"eighty":13.133536,"marketCap":1038701788},{"date":"2023-04-28","current":2.932088,"twenty":5.726233,"median":7.998046,"eighty":13.136199,"marketCap":1041093536},{"date":"2023-05-05","current":2.771386,"twenty":5.536171,"median":7.943558,"eighty":13.136199,"marketCap":984033273},{"date":"2023-05-12","current":2.975648,"twenty":5.442294,"median":7.932539,"eighty":13.136199,"marketCap":1050433502},{"date":"2023-05-19","current":3.089052,"twenty":5.341054,"median":7.932539,"eighty":13.136199,"marketCap":1090466310},{"date":"2023-05-26","current":2.874844,"twenty":5.253436,"median":7.932539,"eighty":13.136199,"marketCap":1014848784},{"date":"2023-06-02","current":2.846736,"twenty":5.130475,"median":7.932539,"eighty":13.136199,"marketCap":1004926122},{"date":"2023-06-09","current":3.07839,"twenty":5.004569,"median":7.932539,"eighty":13.136199,"marketCap":1086702542},{"date":"2023-06-16","current":3.058036,"twenty":4.918423,"median":7.932539,"eighty":13.136199,"marketCap":1079517166},{"date":"2023-06-23","current":2.916523,"twenty":4.864674,"median":7.935774,"eighty":13.138862,"marketCap":1029561696},{"date":"2023-06-30","current":2.952386,"twenty":4.815342,"median":7.93772,"eighty":13.141525,"marketCap":1042221644},{"date":"2023-07-07","current":2.944631,"twenty":4.771165,"median":7.93772,"eighty":13.141525,"marketCap":1039484358},{"date":"2023-07-14","current":3.066759,"twenty":4.749076,"median":7.93772,"eighty":13.141525,"marketCap":1082596613},{"date":"2023-07-21","current":3.116192,"twenty":4.697536,"median":7.93772,"eighty":13.141525,"marketCap":1100046811},{"date":"2023-07-28","current":3.215057,"twenty":4.671766,"median":7.93772,"eighty":13.141525,"marketCap":1134947207},{"date":"2023-08-04","current":3.279998,"twenty":4.616544,"median":7.93772,"eighty":13.141525,"marketCap":1157871978},{"date":"2023-08-11","current":4.645552,"twenty":4.574583,"median":7.93772,"eighty":13.141525,"marketCap":1075069076},{"date":"2023-08-18","current":4.647031,"twenty":4.574583,"median":7.93772,"eighty":13.141525,"marketCap":1075411237},{"date":"2023-08-25","current":4.663295,"twenty":4.574583,"median":7.93772,"eighty":13.141525,"marketCap":1079175005},{"date":"2023-09-01","current":4.624853,"twenty":4.574583,"median":7.93772,"eighty":13.141525,"marketCap":1070278826},{"date":"2023-09-08","current":4.647031,"twenty":4.574583,"median":7.93772,"eighty":13.141525,"marketCap":1075411237},{"date":"2023-09-15","current":4.775663,"twenty":4.570147,"median":7.93772,"eighty":13.141525,"marketCap":1105179222},{"date":"2023-09-22","current":4.867332,"twenty":4.570147,"median":7.93772,"eighty":13.141525,"marketCap":1126393189},{"date":"2023-09-29","current":5.173389,"twenty":4.570147,"median":7.93772,"eighty":13.141525,"marketCap":1197220464},{"date":"2023-10-06","current":4.475521,"twenty":4.542915,"median":7.93772,"eighty":13.141525,"marketCap":1035720590},{"date":"2023-10-13","current":4.511006,"twenty":4.484012,"median":7.93772,"eighty":13.141525,"marketCap":1043932448},{"date":"2023-10-20","current":4.482914,"twenty":4.482914,"median":7.93772,"eighty":13.141525,"marketCap":1037431394},{"date":"2023-10-27","current":4.534662,"twenty":4.467537,"median":7.94745,"eighty":13.149513,"marketCap":1049407020},{"date":"2023-11-03","current":4.904296,"twenty":4.458666,"median":7.94745,"eighty":13.149513,"marketCap":1134947207},{"date":"2023-11-10","current":7.439549,"twenty":4.458666,"median":7.935774,"eighty":13.149513,"marketCap":1088071185},{"date":"2023-11-17","current":7.820894,"twenty":4.458666,"median":7.896854,"eighty":13.149513,"marketCap":1143844827},{"date":"2023-11-24","current":7.993518,"twenty":4.458666,"median":7.896854,"eighty":13.149513,"marketCap":1169092039},{"date":"2023-12-01","current":8.460278,"twenty":4.458666,"median":7.896854,"eighty":13.149513,"marketCap":1237357955},{"date":"2023-12-08","current":8.743603,"twenty":4.459848,"median":7.902692,"eighty":13.146851,"marketCap":1278795691},{"date":"2023-12-15","current":8.690189,"twenty":4.459848,"median":7.902692,"eighty":13.146851,"marketCap":1270983658},{"date":"2023-12-22","current":9.616802,"twenty":4.459848,"median":7.934448,"eighty":13.146851,"marketCap":1406505433},{"date":"2023-12-29","current":9.686473,"twenty":4.4563,"median":7.940074,"eighty":13.154839,"marketCap":1416695040},{"date":"2024-01-05","current":9.75382,"twenty":4.452456,"median":7.93987,"eighty":13.154839,"marketCap":1426544994},{"date":"2024-01-12","current":9.809556,"twenty":4.452456,"median":7.93987,"eighty":13.154839,"marketCap":1434696679},{"date":"2024-01-19","current":10.16023,"twenty":4.448612,"median":7.939666,"eighty":13.154839,"marketCap":1485984368},{"date":"2024-01-26","current":10.740814,"twenty":4.452456,"median":7.93987,"eighty":13.154839,"marketCap":1570897761},{"date":"2024-02-02","current":10.601474,"twenty":4.452456,"median":7.93987,"eighty":13.154839,"marketCap":1550518547},{"date":"2024-02-09","current":10.963759,"twenty":4.452456,"median":7.93987,"eighty":13.154839,"marketCap":1603504503},{"date":"2024-02-16","current":11.124,"twenty":4.452456,"median":7.93987,"eighty":13.154839,"marketCap":1626940600},{"date":"2024-02-23","current":10.647921,"twenty":4.452456,"median":7.93987,"eighty":13.154839,"marketCap":1557311618},{"date":"2024-03-01","current":11.10678,"twenty":4.4563,"median":7.940074,"eighty":13.154839,"marketCap":1583804596},{"date":"2024-03-08","current":11.32675,"twenty":4.4563,"median":7.94745,"eighty":13.154839,"marketCap":1615171958},{"date":"2024-03-15","current":10.799262,"twenty":4.4563,"median":7.990262,"eighty":13.154839,"marketCap":1539953125},{"date":"2024-03-22","current":11.659401,"twenty":4.4563,"median":8.049544,"eighty":13.154839,"marketCap":1662607257},{"date":"2024-03-28","current":10.571159,"twenty":4.4563,"median":8.239503,"eighty":13.154839,"marketCap":1507426062},{"date":"2024-04-05","current":10.811142,"twenty":4.452456,"median":8.461702,"eighty":13.154839,"marketCap":1541647243},{"date":"2024-04-12","current":11.186562,"twenty":4.452456,"median":8.566313,"eighty":13.154839,"marketCap":1595181367},{"date":"2024-04-19","current":10.81827,"twenty":4.452456,"median":8.624771,"eighty":13.154839,"marketCap":1542663714},{"date":"2024-04-26","current":11.245964,"twenty":4.4563,"median":8.639313,"eighty":13.154839,"marketCap":1603651956},{"date":"2024-05-03","current":11.324374,"twenty":4.4563,"median":8.690189,"eighty":13.154839,"marketCap":1614833134},{"date":"2024-05-10","current":14.682959,"twenty":4.4563,"median":8.734756,"eighty":13.168154,"marketCap":1565364893},{"date":"2024-05-17","current":13.78037,"twenty":4.4563,"median":8.734756,"eighty":13.224197,"marketCap":1469138999},{"date":"2024-05-24","current":14.166489,"twenty":4.4563,"median":8.734756,"eighty":13.241384,"marketCap":1510303519},{"date":"2024-05-31","current":14.905887,"twenty":4.4563,"median":8.734756,"eighty":13.248042,"marketCap":1589131510},{"date":"2024-06-07","current":15.724962,"twenty":4.4563,"median":8.734756,"eighty":13.254699,"marketCap":1676453895},{"date":"2024-06-14","current":15.619789,"twenty":4.452456,"median":8.72747,"eighty":13.254699,"marketCap":1665241293},{"date":"2024-06-21","current":14.485195,"twenty":4.448612,"median":8.720183,"eighty":13.254699,"marketCap":1544281101},{"date":"2024-06-28","current":14.60949,"twenty":4.437079,"median":8.698559,"eighty":13.248042,"marketCap":1557532358},{"date":"2024-07-05","current":14.552123,"twenty":4.437079,"median":8.698559,"eighty":13.254699,"marketCap":1551416394},{"date":"2024-07-12","current":13.854157,"twenty":4.437079,"median":8.698559,"eighty":13.254699,"marketCap":1477005489},{"date":"2024-07-15","current":13.586443,"twenty":4.437079,"median":8.698559,"eighty":13.254699,"marketCap":1448464320},{"date":"2024-08-02","current":13.149816,"twenty":4.293661,"median":8.639313,"eighty":12.179123,"marketCap":1401915033},{"date":"2024-08-09","current":12.65362,"twenty":4.293661,"median":8.639313,"eighty":12.333841,"marketCap":1357404400},{"date":"2024-08-16","current":12.71449,"twenty":4.293661,"median":8.639313,"eighty":12.422884,"marketCap":1363934183},{"date":"2024-08-23","current":13.275377,"twenty":4.293661,"median":8.639313,"eighty":12.626454,"marketCap":1424102779},{"date":"2024-08-30","current":14.261656,"twenty":4.293661,"median":8.639313,"eighty":13.112996,"marketCap":1529904861},{"date":"2024-09-06","current":13.281679,"twenty":4.293661,"median":8.639313,"eighty":13.211726,"marketCap":1424778831},{"date":"2024-09-13","current":13.861472,"twenty":4.293661,"median":8.639313,"eighty":13.294349,"marketCap":1486975582},{"date":"2024-09-20","current":13.839415,"twenty":4.293661,"median":8.639313,"eighty":13.376841,"marketCap":1484609401},{"date":"2024-09-27","current":14.00327,"twenty":4.293661,"median":8.639313,"eighty":13.543138,"marketCap":1502186744},{"date":"2024-10-04","current":14.854053,"twenty":4.293661,"median":8.639313,"eighty":13.653503,"marketCap":1593453715},{"date":"2024-10-11","current":14.854053,"twenty":4.293661,"median":8.639313,"eighty":13.84826,"marketCap":1593453715},{"date":"2024-10-18","current":14.737464,"twenty":4.293661,"median":8.639313,"eighty":13.994199,"marketCap":1580946760},{"date":"2024-10-25","current":15.008455,"twenty":4.293661,"median":8.639313,"eighty":14.123548,"marketCap":1610016980},{"date":"2024-10-31","current":14.655537,"twenty":4.293661,"median":8.639313,"eighty":14.202306,"marketCap":1572158088},{"date":"2024-11-08","current":15.118742,"twenty":4.28479,"median":8.64118,"eighty":14.37096,"marketCap":1621847884},{"date":"2024-11-15","current":13.409306,"twenty":4.28479,"median":8.692753,"eighty":14.37096,"marketCap":1673883715},{"date":"2024-11-22","current":14.009118,"twenty":4.28479,"median":8.746428,"eighty":14.37096,"marketCap":1748758223},{"date":"2024-11-29","current":15.251971,"twenty":4.28479,"median":8.78252,"eighty":14.384136,"marketCap":1903903601},{"date":"2024-12-06","current":15.416785,"twenty":4.28479,"median":8.81344,"eighty":14.484602,"marketCap":1924477227},{"date":"2024-12-13","current":14.881817,"twenty":4.28479,"median":8.908125,"eighty":14.552123,"marketCap":1857697260},{"date":"2024-12-20","current":12.709526,"twenty":4.28479,"median":8.950817,"eighty":14.552123,"marketCap":1586530122},{"date":"2024-12-27","current":12.995923,"twenty":4.28479,"median":9.012663,"eighty":14.552123,"marketCap":1622281013},{"date":"2025-01-03","current":12.674402,"twenty":4.28479,"median":9.065008,"eighty":14.552123,"marketCap":1582145578},{"date":"2025-01-10","current":12.901358,"twenty":4.275919,"median":9.188137,"eighty":14.552123,"marketCap":1610476474},{"date":"2025-01-17","current":14.179335,"twenty":4.275919,"median":9.277741,"eighty":14.552123,"marketCap":1770006394},{"date":"2025-01-24","current":13.960485,"twenty":4.275919,"median":9.31881,"eighty":14.552123,"marketCap":1742687317},{"date":"2025-01-31","current":15.316816,"twenty":4.275919,"median":9.382279,"eighty":14.568402,"marketCap":1911998142},{"date":"2025-02-07","current":15.738305,"twenty":4.275919,"median":9.466344,"eighty":14.652386,"marketCap":1964612662},{"date":"2025-02-14","current":15.435698,"twenty":4.275919,"median":9.483084,"eighty":14.687048,"marketCap":1926838135},{"date":"2025-02-21","current":16.178708,"twenty":4.275919,"median":9.514397,"eighty":14.715407,"marketCap":2019588089},{"date":"2025-02-28","current":15.284394,"twenty":4.275919,"median":9.568033,"eighty":14.816241,"marketCap":1907950871},{"date":"2025-03-07","current":19.286086,"twenty":4.270877,"median":9.582779,"eighty":14.884457,"marketCap":1781050742},{"date":"2025-03-14","current":19.942323,"twenty":4.270877,"median":9.582779,"eighty":14.985042,"marketCap":1841653603},{"date":"2025-03-21","current":19.862116,"twenty":4.270877,"median":9.595365,"eighty":15.085182,"marketCap":1834246586},{"date":"2025-03-28","current":19.719932,"twenty":4.270877,"median":9.649313,"eighty":15.125044,"marketCap":1821115967},{"date":"2025-04-04","current":20.186589,"twenty":4.270877,"median":9.689317,"eighty":15.233006,"marketCap":1864211334},{"date":"2025-04-11","current":16.708531,"twenty":4.275919,"median":9.707094,"eighty":15.273586,"marketCap":1543016172},{"date":"2025-04-17","current":18.524121,"twenty":4.275919,"median":9.710303,"eighty":15.333027,"marketCap":1710684087},{"date":"2025-04-21","current":18.509538,"twenty":4.270877,"median":9.726256,"eighty":15.350956,"marketCap":1709337357}],"updateTime":1745355810256}}}